{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:27:30Z","timestamp":1788798450703,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T00:00:00Z","timestamp":1716076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.tranon.2024.102003","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T12:55:55Z","timestamp":1717592155000},"page":"102003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder cancer"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6203-6613","authenticated-orcid":false,"given":"Luis Eduardo Rosa","family":"Zucca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina","family":"Laus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9802-8236","authenticated-orcid":false,"given":"Bruna Pereira","family":"Sorroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduarda","family":"Paro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7470-4655","authenticated-orcid":false,"given":"Luciane","family":"Sussuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6713-6864","authenticated-orcid":false,"given":"Rui Ferreira","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8363-3513","authenticated-orcid":false,"given":"Gustavo Ramos","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5404-9748","authenticated-orcid":false,"given":"Gustavo Noriz","family":"Berardinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8230-1218","authenticated-orcid":false,"given":"Lidia Maria Rebolho Batista","family":"Arantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9639-7940","authenticated-orcid":false,"given":"Rui Manuel","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0002-3507","authenticated-orcid":false,"given":"Flavio Mavignier","family":"C\u00e1rcano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2024.102003_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/medsci8010015","article-title":"Epidemiology of Bladder Cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Medical sciences"},{"key":"10.1016\/j.tranon.2024.102003_bib0002","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of bladder cancer in 2023: a systematic review of risk factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tranon.2024.102003_bib0003","unstructured":"Bladder cancer \u2014 cancer stat facts. Accessed in March 4th, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html."},{"key":"10.1016\/j.tranon.2024.102003_bib0004","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tranon.2024.102003_bib0005","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus calmette-gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tranon.2024.102003_bib0006","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"167","author":"Morales","year":"1976","journal-title":"J. Urol."},{"key":"10.1016\/j.tranon.2024.102003_bib0007","doi-asserted-by":"crossref","DOI":"10.1111\/apm.13011","article-title":"Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections","volume":"128","author":"Larsen","year":"2020","journal-title":"APMIS"},{"key":"10.1016\/j.tranon.2024.102003_bib0008","article-title":"Nonmuscle invasive bladder cancer: developing drugs and biologics for treatment (Draft)","year":"2016","journal-title":"Guidance"},{"key":"10.1016\/j.tranon.2024.102003_bib0009","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International bladder cancer group consensus statement on clinical trial design for patients with Bacillus Calmette-Gu\u00e9rin\u2013exposed high-risk non\u2013muscle-invasive bladder cancer","volume":"82","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tranon.2024.102003_bib0010","unstructured":"NCCN Guidelines version 3.2021. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Accessed March 14, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"10.1016\/j.tranon.2024.102003_bib0011","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2024.102003_bib0012","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2024.102003_bib0013","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2022.04.016","article-title":"Patient-reported outcomes from JAVELIN bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for advanced urothelial carcinoma","volume":"83","author":"Grivas","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tranon.2024.102003_bib0014","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2024.102003_bib0015","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0738-1","article-title":"Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy","volume":"12","author":"Zhao","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tranon.2024.102003_bib0016","first-page":"1","article-title":"Microsatellite instability: a review of what the oncologist should know","volume":"20","author":"Li","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.tranon.2024.102003_bib0017","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2024.102003_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13010131","article-title":"Immune checkpoint inhibitors for the treatment of bladder cancer","volume":"13","author":"Lopez-Beltran","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2024.102003_bib0019","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/iju.14921","article-title":"Predictive biomarkers of response to bacillus Calmette-Gu\u00e9rin immunotherapy and bacillus Calmette-Gu\u00e9rin failure for non-muscle invasive bladder cancer","volume":"29","author":"Wang","year":"2022","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.tranon.2024.102003_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12894-022-01044-1","article-title":"Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer","volume":"22","author":"Mahmoud","year":"2022","journal-title":"BMC Urol."},{"key":"10.1016\/j.tranon.2024.102003_bib0021","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.urolonc.2020.06.007","article-title":"TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer","volume":"40","author":"Attalla","year":"2022","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.tranon.2024.102003_bib0022","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","article-title":"Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy","volume":"56","author":"van Rhijn","year":"2009","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tranon.2024.102003_bib0023","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/andr.12200","article-title":"Absence of microsatellite instability and BRAF (V600E) mutation in testicular germ cell tumors","volume":"4","author":"C\u00e1rcano","year":"2016","journal-title":"Andrology"},{"key":"10.1016\/j.tranon.2024.102003_bib0024","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3389\/fimmu.2023.1062856","article-title":"Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets","volume":"14","author":"Marques","year":"2023","journal-title":"Front. Immunol"},{"key":"10.1016\/j.tranon.2024.102003_bib0025","doi-asserted-by":"crossref","first-page":"28691","DOI":"10.18632\/oncotarget.25611","article-title":"Advantage of HSP110 (T17) marker inclusion for microsatellite instability (MSI) detection in colorectal cancer patients","volume":"9","author":"Berardinelli","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2024.102003_bib0026","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41431-022-01104-y","article-title":"Association of microsatellite instability (MSI) status with the 5-year outcome and genetic ancestry in a large Brazilian cohort of colorectal cancer","volume":"30","author":"Berardinelli","year":"2022","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.tranon.2024.102003_bib0027","doi-asserted-by":"crossref","DOI":"10.1007\/s10147-024-02494-3","article-title":"PD-L1 expression and microsatellite instability (MSI) in cancer of unknown primary site","author":"Junior","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2024.102003_bib0028","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1136\/jclinpath-2020-206832","article-title":"PD-L1 expression by tumor proportion score (TPS) and combined positive score (CPS) are similar in non-small cell lung cancer (NSCLC)","volume":"74","author":"De Marchi","year":"2021","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.tranon.2024.102003_bib0029","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/modpathol.2017.188","article-title":"Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression","volume":"31","author":"Tretiakova","year":"2018","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.tranon.2024.102003_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","author":"He","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.tranon.2024.102003_bib0031","unstructured":"Pancancer IO 360 gene expression panel | nanostring technologies. 2024 Accessed in March 14, 2024. https:\/\/nanostring.com\/products\/ncounter-assays-panels\/oncology\/pancancer-io-360\/."},{"key":"10.1016\/j.tranon.2024.102003_bib0032","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.eururo.2020.06.048","article-title":"Identification of differential tumor subtypes of T1 bladder cancer","volume":"78","author":"Robertson","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tranon.2024.102003_bib0033","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-09-3323","article-title":"Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers","volume":"16","author":"Kim","year":"2010","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.tranon.2024.102003_bib0034","series-title":"Ggplot2: Elegant Graphics For Data Analysis","author":"Wickham","year":"2016"},{"key":"10.1016\/j.tranon.2024.102003_bib0035","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2023.41.16_suppl.4570","article-title":"Mismatch repair deficiency and microsatellite instability-high in urothelial carcinoma: a systematic review and meta-analysis","volume":"41","author":"Chandran","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tranon.2024.102003_bib0036","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00432-022-04412-4","article-title":"Pembrolizumab for all","volume":"149","author":"Kim","year":"2023","journal-title":"J Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.tranon.2024.102003_bib0037","article-title":"Immune checkpoint inhibitors as a treatment option for bladder cancer: current evidence","volume":"15","author":"Okobi","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.tranon.2024.102003_bib0038","doi-asserted-by":"crossref","first-page":"690","DOI":"10.21037\/atm.2019.10.24","article-title":"PD-L1 assessment in urothelial carcinoma: a practical approach","volume":"7","author":"Eckstein","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.tranon.2024.102003_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.801493","article-title":"Targeting TIGIT inhibits bladder cancer metastasis through suppressing IL-32","volume":"12","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tranon.2024.102003_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114890","article-title":"B7-H3 immunoregulatory roles in cancer","volume":"163","author":"Mortezaee","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tranon.2024.102003_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094969","article-title":"Elevated expression of the immune checkpoint ligand CD276 (B7-H3) in urothelial carcinoma cell lines correlates negatively with the cell proliferation","volume":"23","author":"Harland","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2024.102003_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114890","article-title":"B7-H3 immunoregulatory roles in cancer","volume":"163","author":"Mortezaee","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tranon.2024.102003_bib0043","article-title":"mTORC1 upregulates B7-H3\/CD276 to inhibit antitumor T cells and drive tumor immune evasion","volume":"14","author":"Liu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2024.102003_bib0044","doi-asserted-by":"crossref","DOI":"10.1186\/s12894-021-00829-0","article-title":"Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma","volume":"21","author":"Aicher","year":"2021","journal-title":"BMC Urol."},{"key":"10.1016\/j.tranon.2024.102003_bib0045","doi-asserted-by":"crossref","DOI":"10.1186\/s12894-022-01044-1","article-title":"Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer","volume":"22","author":"Mahmoud","year":"2022","journal-title":"BMC Urol."},{"key":"10.1016\/j.tranon.2024.102003_bib0046","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243379","article-title":"Serum soluble B7-H3 is a prognostic marker for patients with non-muscle-invasive bladder cancer","volume":"15","author":"Azuma","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2024.102003_bib0047","article-title":"B7-H3\/CD276: an emerging cancer immunotherapy","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tranon.2024.102003_bib0048","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tranon.2024.102003_bib0049","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004424","article-title":"Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I\/II trial","volume":"10","author":"Aggarwal","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tranon.2024.102003_bib0050","doi-asserted-by":"crossref","first-page":"S760","DOI":"10.1016\/j.annonc.2022.07.609","article-title":"481P A phase I first-in-human study of XL092 in patients (pts) with locally advanced or metastatic solid tumors: results from dose-escalation of XL092 alone and in combination with atezolizumab","volume":"33","author":"Sharma","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2024.102003_bib0051","doi-asserted-by":"crossref","DOI":"10.1177\/11786469211065612","article-title":"Indoleamine 2,3-dioxygenase-1 expression is changed during bladder cancer cell invasion","volume":"15","author":"Santos","year":"2022","journal-title":"Int. J. Tryptophan Res."},{"key":"10.1016\/j.tranon.2024.102003_bib0052","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.tranon.2018.11.012","article-title":"Overexpression of indoleamine 2,3-dioxygenase 1 promotes epithelial-mesenchymal transition by activation of the IL-6\/STAT3\/PD-L1 pathway in bladder cancer","volume":"12","author":"Zhang","year":"2019","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.tranon.2024.102003_bib0053","article-title":"Prognostic role of indoleamine 2,3-dioxygenase 1 expression in solid tumors: a systematic review and meta-analysis","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193652332400130X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193652332400130X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T18:08:55Z","timestamp":1724868535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193652332400130X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":53,"alternative-id":["S193652332400130X"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2024.102003","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2024.102003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102003"}}